Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | QDPR | P09417 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3204554 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL717963 | 0.78 | — | — | |
| SCHEMBL13437768 | 0.73 | NCF1 (0.37) | NCF1QDPRALDH1A1 | |
| Hydrochloric Acid SCHEMBL20819822 | 0.73 | NOS2 (0.42) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL909692 | 0.73 | NOS2 (0.42) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL24378727 | 0.73 | NCF1 (0.33) | NCF1ALDH1A1 | |
| SCHEMBL12243298 | 0.73 | SMN1; SMN2 (0.33) | SMN1; SMN2TP53NCF1QDPRALDH1A1 | |
| SCHEMBL3478768 | 0.73 | TP53 (0.60) | SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL23794214 | 0.71 | NCF1 (0.36) | NCF1QDPRALDH1A1 | |
| SCHEMBL803894 | 0.71 | NOS2 (0.57) | SMN1; SMN2NCF1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025098509-A1 | PYRROLIDINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF IN MEDICINE | 康百达（四川）生物医药科技有限公司 | 2025-05-15 | — | — | WO | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | SMN1; SMN2 1352/4885TP53 860/4885NCF1 2055/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | SMN1; SMN2 1352/4885TP53 860/4885NCF1 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.